Baseline characteristics for patients with MTNKN and CNS relapse
| Patient characteristics (n = 135) . | |
|---|---|
| Age, median (range), y | 59.5 (20-81) |
| Age | n (%) |
| ≤60 y | 71 (53) |
| >60 y | 63 (47) |
| Missing | 1 (1) |
| Sex | |
| Male | 56 (41) |
| Female | 79 (59) |
| MTNKN histology | |
| PTCL, NOS | 34 (25) |
| TFH-TCL (including AITL) | 20 (15) |
| ALCL, ALK+ | 1 (1) |
| ALCL, ALK– | 18 (13) |
| ALCL, ALKu | 0 (0) |
| ALCL, BIA | 0 (0) |
| ENKTL | 7 (5) |
| SPTCL (includes SPTCL and PCGD-TCL) | 2 (1) |
| EATL (includes EATL and MEITL) | 7 (5) |
| HSTCL | 2 (1) |
| MF/SS | 18 (13) |
| Other primary cutaneous TCL | 2 (1) |
| ATLL | 14 (10) |
| T-PLL | 3 (2) |
| T-LGL | 2 (1) |
| ANKL | 3 (2) |
| CLD-NK | 1 (1) |
| T-IOL | 1 (1) |
| TCL UNS | 0 (0) |
| ECOG PS | |
| 0 | 48 (36) |
| 1 | 46 (34) |
| 2 | 15 (11) |
| 3 | 4 (3) |
| 4 | 3 (2) |
| Missing | 19 (14) |
| B symptoms | |
| Yes | 69 (51) |
| No | 47 (35) |
| Missing | 19 (14) |
| Elevated LDH | |
| Yes | 55 (41) |
| No | 76 (56) |
| Missing | 4 (3) |
| Hemoglobin | |
| <11 g/dL | 40 (30) |
| ≥11 g/dL | 86 (64) |
| Missing | 9 (7) |
| Platelet count | |
| <150 × 109/L | 30 (22) |
| ≥150 × 109/L | 90 (67) |
| Missing | 15 (11) |
| Ann Arbor stage | |
| I | 18 (13) |
| II | 11 (8) |
| III | 17 (13) |
| IV | 78 (58) |
| Missing/not applicable | 11 (8) |
| Sites of EN involvement (excluding BM/PB) | |
| None | 45 (33) |
| Liver | 13 (10) |
| GI tract | 18 (13) |
| GU tract | 4 (3) |
| Breast | 3 (2) |
| Testicles | 1 (1) |
| Skin | 34 (25) |
| Bone | 16 (12) |
| Other | 14 (10) |
| Lung | 19 (14) |
| Soft tissue | 14 (10) |
| Sinus | 6 (4) |
| Pleura | 2 (1) |
| Peritoneum | 3 (2) |
| Missing | 3 (2) |
| BM/PB involvement | |
| Yes | 61 (45) |
| No | 56 (41) |
| Missing | 18 (13) |
| ≥2 sites of EN involvement (including BM/PB) | |
| Yes | 59 (44) |
| No | 68 (50) |
| Missing | 8 (6) |
| IPI score | |
| 0 | 19 (14) |
| 1 | 21 (16) |
| 2 | 33 (24) |
| 3 | 45 (33) |
| 4 | 13 (10) |
| 5 | 4 (3) |
| Patient characteristics (n = 135) . | |
|---|---|
| Age, median (range), y | 59.5 (20-81) |
| Age | n (%) |
| ≤60 y | 71 (53) |
| >60 y | 63 (47) |
| Missing | 1 (1) |
| Sex | |
| Male | 56 (41) |
| Female | 79 (59) |
| MTNKN histology | |
| PTCL, NOS | 34 (25) |
| TFH-TCL (including AITL) | 20 (15) |
| ALCL, ALK+ | 1 (1) |
| ALCL, ALK– | 18 (13) |
| ALCL, ALKu | 0 (0) |
| ALCL, BIA | 0 (0) |
| ENKTL | 7 (5) |
| SPTCL (includes SPTCL and PCGD-TCL) | 2 (1) |
| EATL (includes EATL and MEITL) | 7 (5) |
| HSTCL | 2 (1) |
| MF/SS | 18 (13) |
| Other primary cutaneous TCL | 2 (1) |
| ATLL | 14 (10) |
| T-PLL | 3 (2) |
| T-LGL | 2 (1) |
| ANKL | 3 (2) |
| CLD-NK | 1 (1) |
| T-IOL | 1 (1) |
| TCL UNS | 0 (0) |
| ECOG PS | |
| 0 | 48 (36) |
| 1 | 46 (34) |
| 2 | 15 (11) |
| 3 | 4 (3) |
| 4 | 3 (2) |
| Missing | 19 (14) |
| B symptoms | |
| Yes | 69 (51) |
| No | 47 (35) |
| Missing | 19 (14) |
| Elevated LDH | |
| Yes | 55 (41) |
| No | 76 (56) |
| Missing | 4 (3) |
| Hemoglobin | |
| <11 g/dL | 40 (30) |
| ≥11 g/dL | 86 (64) |
| Missing | 9 (7) |
| Platelet count | |
| <150 × 109/L | 30 (22) |
| ≥150 × 109/L | 90 (67) |
| Missing | 15 (11) |
| Ann Arbor stage | |
| I | 18 (13) |
| II | 11 (8) |
| III | 17 (13) |
| IV | 78 (58) |
| Missing/not applicable | 11 (8) |
| Sites of EN involvement (excluding BM/PB) | |
| None | 45 (33) |
| Liver | 13 (10) |
| GI tract | 18 (13) |
| GU tract | 4 (3) |
| Breast | 3 (2) |
| Testicles | 1 (1) |
| Skin | 34 (25) |
| Bone | 16 (12) |
| Other | 14 (10) |
| Lung | 19 (14) |
| Soft tissue | 14 (10) |
| Sinus | 6 (4) |
| Pleura | 2 (1) |
| Peritoneum | 3 (2) |
| Missing | 3 (2) |
| BM/PB involvement | |
| Yes | 61 (45) |
| No | 56 (41) |
| Missing | 18 (13) |
| ≥2 sites of EN involvement (including BM/PB) | |
| Yes | 59 (44) |
| No | 68 (50) |
| Missing | 8 (6) |
| IPI score | |
| 0 | 19 (14) |
| 1 | 21 (16) |
| 2 | 33 (24) |
| 3 | 45 (33) |
| 4 | 13 (10) |
| 5 | 4 (3) |
AITL, angioimmunoblastic T-cell lymphoma; ALKu, ALK status unknown; ANKL, aggressive NK-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; BIA, breast implant associated; CLD-NK, chronic lymphoproliferative disorder of NK-cells; ECOG PS, Eastern Cooperative Oncology Group performance status; EN, extranodal; GI, gastrointestinal; GU, genitourinary; HSTCL, hepatosplenic T-cell lymphoma; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; T-IOL, T-cell intraocular lymphoma; T-LGL, T-cell large granular lymphocytic leukemia; T-PLL, T-cell prolymphocytic leukemia; TFH-TCL, T-follicular helper T-cell lymphoma; UNS, unspecified.